PARTICIPA

PARTICIPA

viernes, 11 de enero de 2019

Algunos articulos sobre NCD, CRONICIDAD.


1.Patient-centered medical home care access among adults with chronic conditions: National Estimates from the medical expenditure panel survey.

Almalki ZS, Karami NA, Almsoudi IA, Alhasoun RK, Mahdi AT, Alabsi EA, Alshahrani SM, Alkhdhran ND, Alotaib TM.

BMC Health Serv Res. 2018 Sep 27;18(1):744. doi: 10.1186/s12913-018-3554-3.

PMID: 30261881 [PubMed - indexed for MEDLINE] Free PMC Article

Similar articles
2.Individual user involvement at Healthy Life Centres: a qualitative study exploring the perspective of health professionals.

Sagsveen E, Rise MB, Grønning K, Bratås O.

Int J Qual Stud Health Well-being. 2018 Dec;13(1):1492291. doi: 10.1080/17482631.2018.1492291.

PMID: 30010499 [PubMed - indexed for MEDLINE] Free PMC Article

Similar articles
3.Use of participatory visual narrative methods to explore older adults' experiences of managing multiple chronic conditions during care transitions.

Backman C, Stacey D, Crick M, Cho-Young D, Marck PB.

BMC Health Serv Res. 2018 Jun 20;18(1):482. doi: 10.1186/s12913-018-3292-6.

PMID: 29925369 [PubMed - indexed for MEDLINE] Free PMC Article

Similar articles
4.What are the effective elements in patient-centered and multimorbidity care? A scoping review.

Poitras ME, Maltais ME, Bestard-Denommé L, Stewart M, Fortin M.

BMC Health Serv Res. 2018 Jun 14;18(1):446. doi: 10.1186/s12913-018-3213-8. Review.

PMID: 29898713 [PubMed - indexed for MEDLINE] Free PMC Article

Similar articles
5.Countries urged to take tough action to prevent NCDs.

[No authors listed]

Bull World Health Organ. 2017 Oct 1;95(10):672-673. doi: 10.2471/BLT.17.031017.

PMID: 29147040 [PubMed - indexed for MEDLINE] Free PMC Article

Similar articles

Influenza communication guide: How to increase influenza vaccination uptake and promote preventive measures to limit its spread

https://ecdc.europa.eu/en/publications-data/communication-guidelines-influenza-vaccination


Enviado desde mi iPhone

jueves, 3 de enero de 2019

The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. - PubMed - NCBI

The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. - PubMed - NCBI

The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality.

Abstract

BACKGROUND: Patient satisfaction is a widely used health care quality metric. However, the relationship between patient satisfaction and health care utilization, expenditures, and outcomes remains ill defined.

METHODS: We conducted a prospective cohort study of adult respondents (N = 51,946) to the 2000 through 2007 national Medical Expenditure Panel Survey, including 2 years of panel data for each patient and mortality follow-up data through December 31, 2006, for the 2000 through 2005 subsample (n = 36,428). Year 1 patient satisfaction was assessed using 5 items from the Consumer Assessment of Health Plans Survey. We estimated the adjusted associations between year 1 patient satisfaction and year 2 health care utilization (any emergency department visits and any inpatient admissions), year 2 health care expenditures (total and for prescription drugs), and mortality during a mean follow-up duration of 3.9 years.

RESULTS: Adjusting for sociodemographics, insurance status, availability of a usual source of care, chronic disease burden, health status, and year 1 utilization and expenditures, respondents in the highest patient satisfaction quartile (relative to the lowest patient satisfaction quartile) had lower odds of any emergency department visit (adjusted odds ratio [aOR], 0.92; 95% CI, 0.84-1.00), higher odds of any inpatient admission (aOR, 1.12; 95% CI, 1.02-1.23), 8.8% (95% CI, 1.6%-16.6%) greater total expenditures, 9.1% (95% CI, 2.3%-16.4%) greater prescription drug expenditures, and higher mortality (adjusted hazard ratio, 1.26; 95% CI, 1.05-1.53).

CONCLUSION: In a nationally representative sample, higher patient satisfaction was associated with less emergency department use but with greater inpatient use, higher overall health care and prescription drug expenditures, and increased mortality.



Enviado desde mi iPhone

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia | NEJM

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia | NEJM

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Abstract

Background

Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events.

Methods

We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Results

A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).

Conclusions

Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361.)

Digital Object ThumbnailFREE QUICK TAKE VIDEO SUMMARYCardiovascular Risk Reduction with Icosapent Ethyl 01:45



Enviado desde mi iPhone